Publication

Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy

Signore, A., Lauri, C., Auletta, S., Varani, M., Onofrio, L., Glaudemans, A. W. J. M., Panzuto, F. & Marchetti, P., 25-Mar-2020, In : Cancers. 12, 4, 18 p., 781.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Signore, A., Lauri, C., Auletta, S., Varani, M., Onofrio, L., Glaudemans, A. W. J. M., ... Marchetti, P. (2020). Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers, 12(4), [781]. https://doi.org/10.3390/cancers12040781

Author

Signore, Alberto ; Lauri, Chiara ; Auletta, Sveva ; Varani, Michela ; Onofrio, Livia ; Glaudemans, Andor W J M ; Panzuto, Francesco ; Marchetti, Paolo. / Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors : Two Examples of How Tissue Characterization May Influence the Choice of Therapy. In: Cancers. 2020 ; Vol. 12, No. 4.

Harvard

Signore, A, Lauri, C, Auletta, S, Varani, M, Onofrio, L, Glaudemans, AWJM, Panzuto, F & Marchetti, P 2020, 'Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy', Cancers, vol. 12, no. 4, 781. https://doi.org/10.3390/cancers12040781

Standard

Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors : Two Examples of How Tissue Characterization May Influence the Choice of Therapy. / Signore, Alberto; Lauri, Chiara; Auletta, Sveva; Varani, Michela; Onofrio, Livia; Glaudemans, Andor W J M; Panzuto, Francesco; Marchetti, Paolo.

In: Cancers, Vol. 12, No. 4, 781, 25.03.2020.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Signore A, Lauri C, Auletta S, Varani M, Onofrio L, Glaudemans AWJM et al. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers. 2020 Mar 25;12(4). 781. https://doi.org/10.3390/cancers12040781


BibTeX

@article{70df5784282c4d58bd3c7aa3451989ba,
title = "Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy",
abstract = "Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the importance of tumoral characterization of hormonal receptors in order to plan a tailored treatment. The most attractive radiopharmaceuticals for breast cancer are 16α-[18F]-fluoro-17β-estradiol for PET assessment of the estrogen expression, radiolabeled monoclonal antibody trastuzumab to image the human epidermal growth factor receptor 2, but also the imaging of androgen receptors with [18F]-fluorodihydrotestosterone.",
keywords = "nuclear medicine, PET, CT, radiopharmaceuticals, therapy decision making, treatment response, personalized medicine, breast cancer, neuroendocrine tumors, ENETS CONSENSUS GUID ELINES, POSITRON-EMISSION-TOMOGRAPHY, RECEPTOR RADIONUCLIDE THERAPY, F-18-FDG PET/CT, IN-VIVO, GA-68-DOTATATE PET/CT, ADJUVANT TRASTUZUMAB, ESTROGEN-RECEPTORS, ANDROGEN RECEPTOR, HORMONE LEVELS",
author = "Alberto Signore and Chiara Lauri and Sveva Auletta and Michela Varani and Livia Onofrio and Glaudemans, {Andor W J M} and Francesco Panzuto and Paolo Marchetti",
year = "2020",
month = "3",
day = "25",
doi = "10.3390/cancers12040781",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors

T2 - Two Examples of How Tissue Characterization May Influence the Choice of Therapy

AU - Signore, Alberto

AU - Lauri, Chiara

AU - Auletta, Sveva

AU - Varani, Michela

AU - Onofrio, Livia

AU - Glaudemans, Andor W J M

AU - Panzuto, Francesco

AU - Marchetti, Paolo

PY - 2020/3/25

Y1 - 2020/3/25

N2 - Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the importance of tumoral characterization of hormonal receptors in order to plan a tailored treatment. The most attractive radiopharmaceuticals for breast cancer are 16α-[18F]-fluoro-17β-estradiol for PET assessment of the estrogen expression, radiolabeled monoclonal antibody trastuzumab to image the human epidermal growth factor receptor 2, but also the imaging of androgen receptors with [18F]-fluorodihydrotestosterone.

AB - Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the importance of tumoral characterization of hormonal receptors in order to plan a tailored treatment. The most attractive radiopharmaceuticals for breast cancer are 16α-[18F]-fluoro-17β-estradiol for PET assessment of the estrogen expression, radiolabeled monoclonal antibody trastuzumab to image the human epidermal growth factor receptor 2, but also the imaging of androgen receptors with [18F]-fluorodihydrotestosterone.

KW - nuclear medicine

KW - PET

KW - CT

KW - radiopharmaceuticals

KW - therapy decision making

KW - treatment response

KW - personalized medicine

KW - breast cancer

KW - neuroendocrine tumors

KW - ENETS CONSENSUS GUID ELINES

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - RECEPTOR RADIONUCLIDE THERAPY

KW - F-18-FDG PET/CT

KW - IN-VIVO

KW - GA-68-DOTATATE PET/CT

KW - ADJUVANT TRASTUZUMAB

KW - ESTROGEN-RECEPTORS

KW - ANDROGEN RECEPTOR

KW - HORMONE LEVELS

U2 - 10.3390/cancers12040781

DO - 10.3390/cancers12040781

M3 - Review article

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 781

ER -

ID: 121008330